Miniatura

Fitxers

710614.pdf (447.72 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-01-19

Llicència de publicació

cc-by (c) Solanich, Xavier et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/177481

Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.conctc.2021.100716

Resum

Introduction: Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients. Methods: and analysis: TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the ef- ficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature≤37.5 ◦C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive hours. Discussion: Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, if effective and safe, a large number of patients could be treated in developed and developing countries.

Matèries

COVID-19, Inflamació, Pulmó

Matèries (anglès)

COVID-19, Inflammation, Lung

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SOLANICH, Xavier, ANTOLÍ, Arnau, PADULLÉS ZAMORA, Núria, FANLO MARESMA, Marta, IRIARTE, Adriana, MITJAVILA VILLERÓ, Francesca, CAPDEVILA, Olga, MOLINA MOLINA, María, SABATER, Joan, BAS, J., MENSA VILARÓ, A., NIUBÓ, Jordi, CALVO, N., BOLIVAR, S., RIGO BONNIN, Raúl, ARREGUI, Laura, TEBÉ, Cristian, HEREU BOHER, Pilar, VIDELA, Sebastià, CORBELLA, Xavier. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol. _Contemporany Clinical Trials_. 2021. Vol. 21, núm. 100716. [consulta: 20 de gener de 2026]. ISSN: 2451-8654. [Disponible a: https://hdl.handle.net/2445/177481]

Exportar metadades

JSON - METS

Compartir registre